A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis
A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis
复制标题
DOI：
10.1053/j.gastro.2006.08.033
复制
发表时间：
2006-11-01
期刊：
影响因子：
29.4
通讯作者：
Rothenberg, Marc E.
中科院分区：
文献类型：
--
作者：
Konikoff, Michael R.;Noel, Richard J.;Rothenberg, Marc E.
背景与目的：嗜酸粒细胞性食管炎是一种越来越受到关注的疾病，具有独特的内镜、组织学和过敏特征。尽管有多种治疗方法被提倡，但尚未进行安慰剂对照试验。我们旨在确定吞咽丙酸氟替卡松（FP）治疗嗜酸粒细胞性食管炎的疗效。
方法：我们对患有活动性嗜酸粒细胞性食管炎的儿科患者进行了一项吞咽FP的随机、双盲、安慰剂对照试验。36名患者被随机分配接受880μg的FP（21名患者）或安慰剂（15名患者），每日两次，为期3个月。主要终点是组织学缓解，定义为嗜酸粒细胞峰值计数……
Background & Aims: Eosinophilic esophagitis is an increasingly recognized disorder with distinctive endoscopic, histologic, and allergic features. Although several therapies are advocated, no placebo-controlled trials have been conducted. We aimed to determine the efficacy of swallowed fluticasone propionate (FP) in the treatment of eosinophilic esophagitis. Methods: We conducted a randomized, double-blind, placebo-con trolled trial of swallowed FP in pediatric patients with active eosinophilic esophagitis. Thirty-six patients were randomly assigned to receive either 880 mu g of FP (21 patients) or placebo (15 patients) divided twice daily for 3 months. The primary end point was histologic remission, defined by a peak eosinophil count of